High-risk human papillomavirus (HPV) testing as triage for women with mild or borderline cytology abnormalities
McIntosh H
Record ID 32013000465
English
Authors' recommendations:
High-risk HPV triage has higher sensitivity and similar specificity compared with repeat cytology for detection of high-grade cervical neoplasia in women with borderline nuclear abnormalities.
High-risk HPV testing has similar sensitivity but lower specificity compared with repeat cytology for detection of high-grade cervical neoplasia in women with mild dyskaryosis.
A UK RCT found that high risk HPV triage could be useful in women over the age of 40 years with low-grade cytological abnormalities, but would not be useful in younger women.
Introduction of reflex high-risk HPV triage in a largely unvaccinated screening population is likely to increase colposcopy referral rates.
There is limited evidence on the clinical effectiveness of delayed HPV triage.
Pilot studies in the English screening programme suggest that HPV triage of low-grade cytology abnormalities is likely to be cost effective, and most cost effective if restricted to women aged 35 years and over, although there is considerable uncertainty around the accruable incremental cost and gains.
Details
Project Status:
Completed
Year Published:
2012
URL for published report:
http://www.healthcareimprovementscotland.org/our_work/technologies_and_medicines/shtg_-_evidence_notes/evidence_note_42.aspx
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Scotland, United Kingdom
MeSH Terms
- Humans
- Papillomavirus Infections
- Uterine Cervical Neoplasms
- Cytological Techniques
- Triage
- Vaginal Smears
Contact
Organisation Name:
Scottish Health Technologies Group
Contact Address:
Scottish Health Technologies Group, Delta House, 50 West Nile Street, Glasgow, G1 2NP Tel: 0141 225 6998
Contact Name:
his.shtg@nhs.scot
Contact Email:
his.shtg@nhs.scot
Copyright:
Healthcare Improvement Scotland
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.